Herceptin,”promising new immunotherapy for metastatic breast canceralpha-HER2 antibody binds receptor, blocks EGF binding & increases HER2 endocytosismonoclonal antibody that recognizes that the epitope is going to be the extracellular domain of Her2; going to prefererntially target the tumor cells b/c they are going to have the highest concentration of Her2 on the plasma membraneblocking antibody (increase endocytosis–> not only prevents binding of ligand

Average Rating 0 out of 5 stars. 0 votes.You must log in to submit a review.Herceptin,”promising new immunotherapy for metastatic[…]

Read more